One can not automatically assume that a failure to show a difference in efficacy implies equally effective treatments. Those who fully read the article will know that the statistical analysis failed to show a difference between the two treatment arms; it does not assert that bevacizumab and ranibizumab are equally effective. The total sample size is insufficient to make a statement regarding which treatment is more effective. This is acknowledged in the article several times, particularly where limitations of the study are discussed.